Identification and Validation of a Ferroptosis-Related Signature for Predicting Prognosis and Immune Microenvironment in Papillary Renal Cell Carcinoma

References

• Courthod G, Tucci M, Di Maio M, Scagliotti GV. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015;96(1):100–112. doi:10.1016/j.critrevonc.2015.05.008
   PubMed Web of Science ®Google Scholar
• Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–552. doi:10.1038/s41585-019-0211-5
   PubMed Web of Science ®Google Scholar
• Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10(6):537–544.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019;31(51):e1904197. doi:10.1002/adma.201904197
   PubMed Web of Science ®Google Scholar
• Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–245. doi:10.1016/j.chembiol.2008.02.010
   PubMedGoogle Scholar
• Zhou L, Zhao B, Zhang L, et al. Alterations in cellular iron metabolism provide more therapeutic opportunities for cancer. Int J Mol Sci. 2018;19(5):1545. doi:10.3390/ijms19051545
   PubMed Web of Science ®Google Scholar
• Li C, Zhang G, Zhao L, Ma Z, Chen H. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. World J Surg Oncol. 2016;14(1):15. doi:10.1186/s12957-016-0769-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei Z, Pan K, Li J, Chen Q. The function and mechanism of ferroptosis in cancer. Apoptosis. 2020;25(11–12):786–798. doi:10.1007/s10495-020-01638-w
   PubMed Web of Science ®Google Scholar
• Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7(7):e2307. doi:10.1038/cddis.2016.208
   PubMed Web of Science ®Google Scholar
• Alvarez SW, Sviderskiy VO, Terzi EM, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature. 2017;551(7682):639–643. doi:10.1038/nature24637
   PubMed Web of Science ®Google Scholar
• Woo SM, Seo SU, Min KJ, et al. Corosolic acid induces non-apoptotic cell death through generation of lipid reactive oxygen species production in human renal carcinoma Caki cells. Int J Mol Sci. 2018;19(5):1309. doi:10.3390/ijms19051309
   PubMed Web of Science ®Google Scholar
• Shao Y, Jia H, Huang L, et al. An original ferroptosis-related gene signature effectively predicts the prognosis and clinical status for colorectal cancer patients. Front Oncol. 2021;11:711776. doi:10.3389/fonc.2021.711776
   PubMed Web of Science ®Google Scholar
• Zhang K, Ping L, Du T, et al. A ferroptosis-related lncRNAs signature predicts prognosis and immune microenvironment for breast cancer. Front Mol Biosci. 2021;8:678877. doi:10.3389/fmolb.2021.678877
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu J, Li J, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signal. 2020;18(1):174. doi:10.1186/s12964-020-00663-1
   PubMed Web of Science ®Google Scholar
• He F, Chen Z, Deng W, et al. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma. Int Immunopharmacol. 2021;98:107789. doi:10.1016/j.intimp.2021.107789
   PubMed Web of Science ®Google Scholar
• Bai D, Feng H, Yang J, et al. Genomic analysis uncovers prognostic and immunogenic characteristics of ferroptosis for clear cell renal cell carcinoma. Mol Ther Nucleic Acids. 2021;25:186–197. doi:10.1016/j.omtn.2021.05.009
   PubMedGoogle Scholar
• Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020;2020. doi:10.1093/database/baaa021
   Web of Science ®Google Scholar
• Bardou P, Mariette J, Escudie F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinform. 2014;15(1):293. doi:10.1186/1471-2105-15-293
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Song W, Shao Y, He X, et al. IGFLR1 as a novel prognostic biomarker in clear cell renal cell cancer correlating with immune infiltrates. Front Mol Biosci. 2020;7:565173. doi:10.3389/fmolb.2020.565173
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Chang K, Yuan C, Liu X. Ferroptosis-related gene signature accurately predicts survival outcomes in patients with clear-cell renal cell carcinoma. Front Oncol. 2021;11:649347. doi:10.3389/fonc.2021.649347
   PubMed Web of Science ®Google Scholar
• Hong Y, Lin M, Ou D, Huang Z, Shen P. A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma. BMC Cancer. 2021;21(1):831. doi:10.1186/s12885-021-08559-0
   PubMed Web of Science ®Google Scholar
• Ohmura S, Marchetto A, Orth MF, et al. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021;20(1):97. doi:10.1186/s12943-021-01393-9
   PubMed Web of Science ®Google Scholar
• Chen WX, Yang LG, Xu LY, et al. Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer. Biosci Rep. 2019;39:BSR20182062.
   PubMed Web of Science ®Google Scholar
• Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW, Guo R. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging. 2020;13(3):3518–3535. doi:10.18632/aging.202292
   PubMedGoogle Scholar
• Ma C, Luo H, Cao J, Gao C, Fa X, Wang G. Independent prognostic implications of RRM2 in lung adenocarcinoma. J Cancer. 2020;11:7009–7022. doi:10.7150/jca.47895
   PubMed Web of Science ®Google Scholar
• Ohashi R, Angori S, Batavia AA, et al. Loss of CDKN1A mRNA and protein expression are independent predictors of poor outcome in chromophobe renal cell carcinoma patients. Cancers. 2020;12(2):465. doi:10.3390/cancers12020465
   PubMed Web of Science ®Google Scholar
• Fan Z, Liu T, Huang H, Lin J, Zeng Z. A ferroptosis-related gene signature for graft loss prediction following renal allograft. Bioengineered. 2021;12(1):4217–4232. doi:10.1080/21655979.2021.1953310
   PubMed Web of Science ®Google Scholar
• Yang Y, Wu J, Cai J, et al. PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells. Int J Cancer. 2015;136(4):E39–50. doi:10.1002/ijc.29150
   PubMed Web of Science ®Google Scholar
• Sharma I, Deng F, Kanwar YS. Modulation of renal injury by variable expression of Myo-Inositol Oxygenase (MIOX) via perturbation in metabolic sensors. Biomedicines. 2020;8(7):217. doi:10.3390/biomedicines8070217
   PubMed Web of Science ®Google Scholar
• Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149(6):1269–1283. doi:10.1016/j.cell.2012.04.026
   PubMed Web of Science ®Google Scholar
• Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62. doi:10.1038/nature14344
   PubMed Web of Science ®Google Scholar
• Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–591. doi:10.1038/s41556-019-0305-6
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhu S, Song X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017;20(7):1692–1704. doi:10.1016/j.celrep.2017.07.055
   PubMed Web of Science ®Google Scholar
• Rhee I. Diverse macrophages polarization in tumor microenvironment. Arch Pharm Res. 2016;39(11):1588–1596. doi:10.1007/s12272-016-0820-y
   PubMed Web of Science ®Google Scholar
• Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33(3):119–126. doi:10.1016/j.it.2011.12.001
   PubMed Web of Science ®Google Scholar